Cargando…
Global facial rejuvenation with one treatment of incobotulinumtoxinA, hyaluronic acid, and calcium hydroxyapatite results in long-term patient-reported satisfaction
BACKGROUND: Global facial rejuvenation using injectables (neuromodulators and fillers) has reported patient satisfaction after 2 treatments: an initial and touch-up treatment at 2–4 weeks afterward. In practice, patients typically receive only 1 treatment and do not return for a touch-up treatment w...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664851/ https://www.ncbi.nlm.nih.gov/pubmed/38028021 http://dx.doi.org/10.1097/JW9.0000000000000124 |
_version_ | 1785148800341377024 |
---|---|
author | Lu, Jasmine Thai Lee, Kachiu C. |
author_facet | Lu, Jasmine Thai Lee, Kachiu C. |
author_sort | Lu, Jasmine Thai |
collection | PubMed |
description | BACKGROUND: Global facial rejuvenation using injectables (neuromodulators and fillers) has reported patient satisfaction after 2 treatments: an initial and touch-up treatment at 2–4 weeks afterward. In practice, patients typically receive only 1 treatment and do not return for a touch-up treatment within a month. OBJECTIVE: The purpose of this study was to assess patient-reported satisfaction after only 1 treatment, thus mimicking real-world scenarios. METHODS: Patients with facial photoaging (Glogau facial aging scale ≥2) were treated with calcium hydroxyapatite, hyaluronic acid 22.5 mg/mL, and incobotulinumtoxinA injections for full facial rejuvenation, with no touch-up treatments. Patients completed the FACE-Q Satisfaction with Facial Appearance survey at baseline and 1- and 3-month post-treatment. The treating physician completed the Global Aesthetic Improvement Scale at 1- and 3-month post-treatment. RESULTS: Twenty-two patients were enrolled in the study, with 1 patient lost to follow-up. There was a significant improvement in mean FACE-Q scores at 1-month (80.1, P = .01) and 3-month (77.9, P = .02) compared to baseline (71.4). Mean Global Aesthetic Improvement Scale scores at 1-month (2.1) and 3-month (2.2) were not statistically significant, indicating sustained improvement at 3 months. The product amount used per patient varied and was not correlated with either score. Limitations included a lack of a control group and follow-up ending at 3 months. Strengths included assessment of patient satisfaction after only 1 treatment, compared to other studies allowing 2 treatments. LIMITATIONS: Limitations include a small sample size and lack of a control group. CONCLUSION: Global full facial rejuvenation using 1 treatment of calcium hydroxyapatite, hyaluronic acid 22.5 mg/mL, and incobotulinumtoxinA provides sustained patient-reported satisfaction at 3 months. |
format | Online Article Text |
id | pubmed-10664851 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-106648512023-11-22 Global facial rejuvenation with one treatment of incobotulinumtoxinA, hyaluronic acid, and calcium hydroxyapatite results in long-term patient-reported satisfaction Lu, Jasmine Thai Lee, Kachiu C. Int J Womens Dermatol Original Research BACKGROUND: Global facial rejuvenation using injectables (neuromodulators and fillers) has reported patient satisfaction after 2 treatments: an initial and touch-up treatment at 2–4 weeks afterward. In practice, patients typically receive only 1 treatment and do not return for a touch-up treatment within a month. OBJECTIVE: The purpose of this study was to assess patient-reported satisfaction after only 1 treatment, thus mimicking real-world scenarios. METHODS: Patients with facial photoaging (Glogau facial aging scale ≥2) were treated with calcium hydroxyapatite, hyaluronic acid 22.5 mg/mL, and incobotulinumtoxinA injections for full facial rejuvenation, with no touch-up treatments. Patients completed the FACE-Q Satisfaction with Facial Appearance survey at baseline and 1- and 3-month post-treatment. The treating physician completed the Global Aesthetic Improvement Scale at 1- and 3-month post-treatment. RESULTS: Twenty-two patients were enrolled in the study, with 1 patient lost to follow-up. There was a significant improvement in mean FACE-Q scores at 1-month (80.1, P = .01) and 3-month (77.9, P = .02) compared to baseline (71.4). Mean Global Aesthetic Improvement Scale scores at 1-month (2.1) and 3-month (2.2) were not statistically significant, indicating sustained improvement at 3 months. The product amount used per patient varied and was not correlated with either score. Limitations included a lack of a control group and follow-up ending at 3 months. Strengths included assessment of patient satisfaction after only 1 treatment, compared to other studies allowing 2 treatments. LIMITATIONS: Limitations include a small sample size and lack of a control group. CONCLUSION: Global full facial rejuvenation using 1 treatment of calcium hydroxyapatite, hyaluronic acid 22.5 mg/mL, and incobotulinumtoxinA provides sustained patient-reported satisfaction at 3 months. Lippincott Williams & Wilkins 2023-11-22 /pmc/articles/PMC10664851/ /pubmed/38028021 http://dx.doi.org/10.1097/JW9.0000000000000124 Text en Copyright © 2023 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of Women’s Dermatologic Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Original Research Lu, Jasmine Thai Lee, Kachiu C. Global facial rejuvenation with one treatment of incobotulinumtoxinA, hyaluronic acid, and calcium hydroxyapatite results in long-term patient-reported satisfaction |
title | Global facial rejuvenation with one treatment of incobotulinumtoxinA, hyaluronic acid, and calcium hydroxyapatite results in long-term patient-reported satisfaction |
title_full | Global facial rejuvenation with one treatment of incobotulinumtoxinA, hyaluronic acid, and calcium hydroxyapatite results in long-term patient-reported satisfaction |
title_fullStr | Global facial rejuvenation with one treatment of incobotulinumtoxinA, hyaluronic acid, and calcium hydroxyapatite results in long-term patient-reported satisfaction |
title_full_unstemmed | Global facial rejuvenation with one treatment of incobotulinumtoxinA, hyaluronic acid, and calcium hydroxyapatite results in long-term patient-reported satisfaction |
title_short | Global facial rejuvenation with one treatment of incobotulinumtoxinA, hyaluronic acid, and calcium hydroxyapatite results in long-term patient-reported satisfaction |
title_sort | global facial rejuvenation with one treatment of incobotulinumtoxina, hyaluronic acid, and calcium hydroxyapatite results in long-term patient-reported satisfaction |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664851/ https://www.ncbi.nlm.nih.gov/pubmed/38028021 http://dx.doi.org/10.1097/JW9.0000000000000124 |
work_keys_str_mv | AT lujasminethai globalfacialrejuvenationwithonetreatmentofincobotulinumtoxinahyaluronicacidandcalciumhydroxyapatiteresultsinlongtermpatientreportedsatisfaction AT leekachiuc globalfacialrejuvenationwithonetreatmentofincobotulinumtoxinahyaluronicacidandcalciumhydroxyapatiteresultsinlongtermpatientreportedsatisfaction |